MIAMI--(

迈阿密--(

BUSINESS WIRE

商业热线

)--First Ascent Biomedical, a pioneer in personalized cancer treatment, today announced a $6 million investment from Vidal Duart Enterprises, Inc., with an additional co-investment from Techstars. The funding will accelerate First Ascent Biomedical’s mission to transform medical oncology with highly individualized, prospective treatment planning technologies that improve patient survival..

)--个性化癌症治疗的先驱First Ascent Biomedical今天宣布由Vidal Duart Enterprises，Inc.投资600万美元，另外还有Techstars的联合投资。这笔资金将加速First Ascent Biomedical的使命，即通过高度个性化的前瞻性治疗计划技术来改变医学肿瘤学，从而提高患者的生存率。。

First Ascent Biomedical’s technology represents a shift from a one-size-fits-all approach to a tailored strategy, offering hope to cancer patients who have exhausted traditional options. The company’s functional precision medicine platform integrates drug testing, DNA/RNA sequencing and AI-guided tumor weakness mapping to test hundreds of FDA-approved drugs against a patient's unique cancer profile.

First Ascent Biomedical的技术代表着从一刀切的方法向量身定制的策略的转变，为已经耗尽传统选择的癌症患者提供了希望。该公司的功能性精准医学平台集成了药物测试、DNA/RNA测序和AI引导的肿瘤弱点定位，以针对患者独特的癌症特征测试数百种FDA批准的药物。

The platform delivers a highly personalized, actionable plan to a patient’s physician in an average of 10 days. Results show that First Ascent Biomedical’s technology has significantly improved patient outcomes. Patients treated with decisions guided by the platform demonstrated an 83% greater benefit than those treated with the standard of care of a doctor’s choice..

该平台平均在10天内为患者的医生提供高度个性化的可行计划。结果表明，First Ascent Biomedical的技术显着改善了患者的预后。接受该平台指导的决策治疗的患者比接受医生选择的标准治疗的患者获益高83%。。

The platform’s technology was developed by Dr. Noah Berlow, co-founder and CTO, and Dr. Diana Azzam, First Ascent Biomedical’s co-founder and scientific advisor. Dr. Berlow designed the company’s AI framework. Dr. Azzan brings years of cancer research and a wealth of functional precision medicine expertise to First Ascent Biomedical, currently serving as an assistant professor of environmental health sciences at the Florida International University Robert Stempel College of Public Health and Social Work..

该平台的技术由联合创始人兼首席技术官诺亚·贝娄博士和第一位Ascent Biomedical联合创始人兼科学顾问戴安娜·阿扎姆博士开发。Berlow博士设计了公司的人工智能框架。Azzan博士为First Ascent Biomedical带来了多年的癌症研究和丰富的功能精准医学专业知识，目前担任佛罗里达国际大学罗伯特·斯坦佩尔公共卫生与社会工作学院环境健康科学助理教授。。

The capital raised will support the expansion of First Ascent Biomedical’s operations, including the establishment of a state-of-the-art lab in Florida, where the company will continue its mission to transform cancer care for all patients, especially those in underserved communities.

筹集的资金将支持First Ascent Biomedical业务的扩展，包括在佛罗里达州建立一个最先进的实验室，该公司将继续致力于为所有患者，特别是服务不足社区的患者提供癌症护理。

“The funding we have raised is a defining moment for First Ascent Biomedical and for cancer care,” said Jim Foote, Co-founder and CEO of First Ascent Biomedical. “As someone who tragically lost my son to cancer, I know the devastating toll this disease takes on families. With this fresh capital, we are not just advancing technology—we are giving patients and their families hope.

First Ascent Biomedical联合创始人兼首席执行官吉姆·富特（JimFoote）表示：“我们筹集的资金是First Ascent Biomedical和癌症护理的决定性时刻。”。“作为一个因癌症不幸失去儿子的人，我知道这种疾病给家庭带来了毁灭性的损失。有了这个新的资本，我们不仅仅是在推进技术，我们正在给患者及其家人带来希望。

Florida is where our technology was invented, so we are excited to open our first commercial lab here as we charge forward in making personalized cancer care widely accessible.”.

佛罗里达州是我们技术的发明地，因此我们很高兴在这里开设我们的第一个商业实验室，因为我们正在努力使个性化癌症护理广泛普及。”。

“First Ascent Biomedical is at the forefront of a new era in cancer treatment. Their groundbreaking technology has already proven its potential to save lives and change the trajectory of this disease,” said Carlos Duart, Owner of Vidal Duart Enterprises. “This investment is not just a business decision—it’s a commitment to improving outcomes for cancer patients everywhere.”.

“First Ascent Biomedical处于癌症治疗新时代的前沿。他们开创性的技术已经证明了其挽救生命和改变这种疾病发展轨迹的潜力，”Vidal Duart Enterprises的所有者Carlos Duart说。“这项投资不仅仅是一项商业决策，它是一项致力于改善各地癌症患者预后的承诺。”。

Tina Vidal Duart, Co-owner of Vidal Duart Enterprises, added: “We are proud to support a company that combines innovation with compassion. The work First Ascent Biomedical is doing will have a ripple effect far beyond Florida, giving patients personalized care that improves their chances of survival.

维达尔·杜亚特企业联合所有人蒂娜·维达尔·杜亚特补充道：“我们很自豪能够支持一家将创新与同情心相结合的公司。First Ascent Biomedical正在做的工作将产生远远超出佛罗里达州的涟漪效应，为患者提供个性化护理，提高他们的生存机会。

We are honored to help bring this vision to life.”.

。

“First Ascent Biomedical represents the future of cancer care, where innovation and personalization come together to save lives,” said Andrew Cleland, Chief Investment Officer at Techstars. “The opportunity to transform medical oncology through precision medicine is immense, and First Ascent Biomedical is paving the way to make customized cancer treatment a reality with its drug prediction technologies.”.

Techstars首席投资官安德鲁·克莱兰德（AndrewCleland）表示：“First Ascent Biomedical代表了癌症治疗的未来，创新和个性化共同拯救生命。”。。

About First Ascent Biomedical

关于First Ascent Biomedical

First Ascent Biomedical is a leader in Functional Precision Medicine, leveraging advanced technologies to personalize cancer treatment. With roots in Florida and a commitment to improving patient outcomes, the company’s platform has been shown to significantly outperform standard care, offering a new frontier in oncology..

First Ascent Biomedical是功能精准医学的领导者，利用先进技术个性化癌症治疗。扎根于佛罗里达州并致力于改善患者预后，该公司的平台已显示出明显优于标准护理，为肿瘤学提供了新的前沿。。

About Vidal Duart Enterprises, Inc.

关于Vidal Duart Enterprises，Inc。

Vidal Duart Enterprises is a private investment firm dedicated to empowering transformative ventures. Led by Carlos and Tina Vidal Duart, the firm focuses on supporting groundbreaking innovations that create lasting social and economic impact.

维达尔杜亚特企业是一家私人投资公司，致力于为变革性企业提供支持。该公司由卡洛斯和蒂娜·维达尔·杜亚特（TinaVidalDuart）领导，专注于支持开创性的创新，创造持久的社会和经济影响。

About Techstars

FreeBSD吉祥物

Techstars helps founders succeed. Through our global accelerators, we invest in early-stage startups led by founders building a better future for everyone. We leverage our vast network of alumni, mentors, partners and investors to support entrepreneurs and build thriving startup communities. Since 2006, we have invested in industry-defining companies including Chainalysis, Zipline, DataRobot, Alloy and many, many more.

Techstars帮助创始人取得成功。通过我们的全球加速器，我们投资于由创始人领导的早期初创公司，为每个人创造更美好的未来。我们利用我们庞大的校友、导师、合作伙伴和投资者网络，支持企业家，建立繁荣的创业社区。自2006年以来，我们投资了行业定义公司，包括ChainAnalysis、Zipline、DataRobot、Alloy等。

.

.

www.techstars.com

www.techstars.com